Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma

Miller, 2006, Melanoma, N Engl J Med, 355, 51, 10.1056/NEJMra052166 Chapman, 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, 364, 2507, 10.1056/NEJMoa1103782 Sosman, 2012, Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib, N Engl J Med, 366, 707, 10.1056/NEJMoa1112302 Hauschild, 2012, Dabrafenib in BRAF-mutated metastatic melanoma: a multicenter, open-label, phase 3 randomised controlled trial, Lancet, 380, 358, 10.1016/S0140-6736(12)60868-X Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766 Sasaki, 2004, BRAF point mutations in primary melanoma show different prevalences by subtype, J Invest Dermatol, 123, 177, 10.1111/j.0022-202X.2004.22722.x Lang, 2005, Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes, J Invest Dermatol, 125, 575, 10.1111/j.0022-202X.2005.23833.x Stroup, 2000, Meta-analysis of observational studies in epidemiology: a proposal for reporting; meta-analysis of observational studies in epidemiology (MOOSE) group, JAMA, 283, 2008, 10.1001/jama.283.15.2008 Higgins, 2003, Measuring inconsistency in meta-analysis, BMJ, 327, 557, 10.1136/bmj.327.7414.557 Egger, 2001 Higgins, 2002, Quantifying heterogeneity in a meta-analysis, Stat Med, 21, 1539, 10.1002/sim.1186 Uribe, 2003, BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin, Am J Dermatopathol, 25, 365, 10.1097/00000372-200310000-00001 Maldonado, 2003, Determinants of BRAF mutations in primary melanomas, J Natl Cancer Inst, 95, 1878, 10.1093/jnci/djg123 Omholt, 2003, NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression, Clin Cancer Res, 9, 6483 Reifenberger, 2004, Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas, Int J Cancer, 109, 377, 10.1002/ijc.11722 Shinozaki, 2004, Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas, Clin Cancer Res, 10, 1753, 10.1158/1078-0432.CCR-1169-3 Thomas, 2004, Tandem BRAF mutations in primary invasive melanomas, J Invest Dermatol, 122, 1245, 10.1111/j.0022-202X.2004.22523.x Deichmann, 2004, B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome, Oncology, 66, 411, 10.1159/000079490 Libra, 2005, Analysis of BRAF mutation in primary and metastatic melanoma, Cell Cycle, 4, 1382, 10.4161/cc.4.10.2026 Akslen, 2005, BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival, J Invest Dermatol, 125, 312, 10.1111/j.0022-202X.2005.23788.x Takata, 2005, Constitutive activation of the mitogen-activated protein kinase signaling pathway in acral melanomas, J Invest Dermatol, 125, 318, 10.1111/j.0022-202X.2005.23812.x Curtin, 2005, Distinct sets of genetic alterations in melanoma, N Engl J Med, 353, 2135, 10.1056/NEJMoa050092 Goel, 2006, Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma, J Invest Dermatol, 126, 154, 10.1038/sj.jid.5700026 Deichmann, 2006, The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites, Int J Oncol, 29, 139 Poynter, 2006, BRAF and NRAS mutations in melanoma and melanocytic nevi, Melanoma Res, 16, 267, 10.1097/01.cmr.0000222600.73179.f3 Saldanha, 2006, Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies, Clin Cancer Res, 12, 4499, 10.1158/1078-0432.CCR-05-2447 Edlundh-Rose, 2006, NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing, Melanoma Res, 16, 471, 10.1097/01.cmr.0000232300.22032.86 Liu, 2007, Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma, J Invest Dermatol, 127, 900, 10.1038/sj.jid.5700632 Thomas, 2007, Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma, Cancer Epidemiol Biomarkers Prev, 16, 991, 10.1158/1055-9965.EPI-06-1038 Akslen, 2008, Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma, Melanoma Res, 18, 29, 10.1097/CMR.0b013e3282f32517 Fargnoli, 2008, MC1R variants increase risk of melanomas harboring BRAF mutations, J Invest Dermatol, 128, 2485, 10.1038/jid.2008.67 Viros, 2008, Improving melanoma classification by integrating genetic and morphologic features, PLoS Med, 5, e120, 10.1371/journal.pmed.0050120 Beadling, 2008, KIT gene mutations and copy number in melanoma subtypes, Clin Cancer Res, 1, 6821, 10.1158/1078-0432.CCR-08-0575 Kannengiesser, 2008, Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas, Mol Oncol, 1, 425, 10.1016/j.molonc.2008.01.002 Dadzie, 2009, RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis, Br J Dermatol, 160, 368, 10.1111/j.1365-2133.2008.08887.x Daniotti, 2009, Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT, J Invest Dermatol, 129, 1759, 10.1038/jid.2008.422 Uribe, 2009, Allelotyping, microsatellite instability, and BRAF mutation analyses in common and atypical melanocytic nevi and primary cutaneous melanomas, Am J Dermatopathol, 31, 354, 10.1097/DAD.0b013e318185d205 Lázár, 2009, Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma, Mod Pathol, 22, 1367, 10.1038/modpathol.2009.109 Hacker, 2010, The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population, J Invest Dermatol, 130, 241, 10.1038/jid.2009.182 Broekaert, 2010, Genetic and morphologic features for melanoma classification, Pigment Cell Melanoma Res, 23, 763, 10.1111/j.1755-148X.2010.00778.x Ellerhorst, 2011, Clinical correlates of NRAS and BRAF mutations in primary human melanoma, Clin Cancer Res, 17, 229, 10.1158/1078-0432.CCR-10-2276 Bauer, 2011, BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site, Pigment Cell Melanoma Res, 24, 345, 10.1111/j.1755-148X.2011.00837.x Qi, 2011, BRAF exon 15 T1799A mutation is common in melanocytic nevi, but less prevalent in cutaneous malignant melanoma, in Chinese Han, J Invest Dermatol, 131, 1129, 10.1038/jid.2010.405 Devitt, 2011, Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma, Pigment Cell Melanoma Res, 24, 666, 10.1111/j.1755-148X.2011.00873.x Si, 2012, Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort, Eur J Cancer, 48, 94, 10.1016/j.ejca.2011.06.056 Ashida, 2012, Assessment of BRAF and KIT mutations in Japanese melanoma patients, J Dermatol Sci, 66, 240, 10.1016/j.jdermsci.2012.03.005 Lee, 2012, Frequency of BRAF mutation and clinical relevance for primary melanomas, Korean J Pathol, 46, 246, 10.4132/KoreanJPathol.2012.46.3.246 Jin, 2013, BRAF mutations and KIT aberrations and their clinicopathological correlation in 202 Korean melanomas, J Invest Dermatol, 133, 579, 10.1038/jid.2012.338 Feller, 2013, Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma, Mod Pathol, 26, 414, 10.1038/modpathol.2012.168 Hacker, 2013, NRAS and BRAF mutations in cutaneous melanoma and the association with MC1R genotype: findings from Spanish and Austrian populations, J Invest Dermatol, 133, 1027, 10.1038/jid.2012.385 Greaves, 2013, Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma, J Mol Diagn, 15, 220, 10.1016/j.jmoldx.2012.10.002 Niu, 2013, Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas, Pigment Cell Melanoma Res, 26, 646, 10.1111/pcmr.12129 Massi, 2013, BRAF and KIT somatic mutations are present in amelanotic melanoma, Melanoma Res, 23, 414, 10.1097/CMR.0b013e32836477d4 Zebary, 2013, KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma, J Dermatol Sci, 72, 284, 10.1016/j.jdermsci.2013.07.013 Lee, 2011, Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis, Br J Dermatol, 164, 776, 10.1111/j.1365-2133.2010.10185.x Kukita, 1989, Clinical features and distribution of malignant melanoma and pigmented nevi on the soles of the feet in Japan, J Invest Dermatol, 92, 210S, 10.1038/jid.1989.67 Rajagopalan, 2002, Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status, Nature, 418, 934, 10.1038/418934a